Leishmania donovani antigens (L. donovani antigens)

Leishmania donovani antigens are a diverse collection of molecular components, including surface glycoproteins (gp63), kinesin-related proteins (K39), and lipophosphoglycans (LPG), derived from the causative agent of visceral leishmaniasis. These antigens play pivotal roles in the parasite's life cycle, particularly in host cell attachment, internalization into macrophages, and the modulation of host immune signaling to favor parasite survival (Srivastava et al., 2011, Journal of Clinical Microbiology). In clinical practice, these antigens are primarily utilized as diagnostic biomarkers, with the rK39 rapid diagnostic test being the gold standard for detecting visceral leishmaniasis in many endemic areas (Burns et al., 1993, Proceedings of the National Academy of Sciences). Furthermore, they are the focus of extensive vaccine research, where they are used to elicit a protective Th1-type cellular immune response characterized by interferon-gamma production (Gillespie et al., 2016, Current Opinion in Immunology). While traditional anti-leishmanial drugs target metabolic pathways, the strategic use of these antigens in immunotherapy represents a promising avenue for long-term disease control and prevention.

Other names

Visceral leishmaniasis antigensL. donovani proteinsKala-azar antigensLeishmania donovani surface antigens

Vaccines targeting these antigens work by priming the host's adaptive immune system, specifically inducing CD4+ and CD8+ T-cell responses that produce pro-inflammatory cytokines like IFN-gamma to activate macrophage-mediated killing of the parasite (Gillespie et al., 2016, Current Opinion in Immunology).